Clinical Trials Logo

Lung Squamous Cell Carcinoma clinical trials

View clinical trials related to Lung Squamous Cell Carcinoma.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT01807546 Completed - Clinical trials for Head and Neck Squamous Cell Carcinoma

Oral Rigosertib for Squamous Cell Carcinoma

Start date: March 2013
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to determine if tumors in patients with papillomavirus (HPV) positive or negative squamous cell carcinoma (SCC) that no longer responds to standard therapy will decrease in size following treatment with the investigational drug, rigosertib sodium (ON 01910.Na). A secondary objective is to determine if treatment with rigosertib causes any side effects. Rigosertib is an investigational drug, which means that it has not been approved by the U.S. Food and Drug Administration (FDA) to treat any diseases. We are studying rigosertib as a new anticancer drug. Tests that we have done in the laboratory suggest that rigosertib works by blocking cell division in cancer cells and causing them to die.